Catalyst

Slingshot members are tracking this event:

Phase 1/2 Preliminary data from Clearside Biomedical's (CLSD) Suprachoroidal CLS-TA - HULK Trial in Diabetic macular edema (DME) due 2Q 2018

Source Link:
http://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-inc-announces-third-quarter-2017-financial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CLSD Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 13, 2017
Occurred Source:
https://globenewswire.com/news-release/2017/11/13/1185058/0/en/Clearside-Biomedical-s-Phase-1-2-Open-Label-Clinical-Trial-of-CLS-TA-With-and-Without-Eylea-in-Diabetic-Macular-Edema-Presented-at-the-American-Academy-of-Ophthalmology-2017-Annual.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2, Preliminary Data, Suprachoroidal Cls-ta, Hulk Trial, Diabetic Macular Edema
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.